Elena CM, Fulvia PF, Emanuela R, Luigi C, et al. A Phase 2, Open Label, Multicenter, Single Arm Trial Evaluating the Activity and Safety of Abemaciclib + Aromatase Inhibitors (AIs) as Second-Line Treatment After First-Line Fulvestrant in Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-Factor Clin Breast Cancer 2025 May 13:S1526-8209(25)00116.
PMID: 40500613